Spyre Therapeutics to Participate in Upcoming November Investor Conferences

WALTHAM, Mass. , Oct. 30, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc.

(NASDAQ: SYRE ), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim's Inaugural Healthcare Innovation Conference Date: Wednesday, November 13, 2024 Time: 2:30pm ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 1:15 pm ET Event: Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024 Time: 10:30 am GMT Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations .



About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.

spyre.com . Follow Spyre Therapeutics on social media: @spyretx and LinkedIn SOURCE Spyre Therapeutics, Inc.

.